HI SCR14

Urges Hawaii's congressional delegation to monitor The Alliance for Hippocratic Medicine v. U.S. Food and Drug Administration, a case pending in the United States District Court for the Northern District of Texas challenging FDA approval of mifepristone.

Requests that Hawaii's congressional delegation take action to limit the case from further restricting access to safe abortion options.

Notes that mifepristone was FDA-approved on September 28, 2000, for use with misoprostol for medical termination of pregnancy through seven weeks gestation, extended to ten weeks gestation in 2016.

States that a ruling against the FDA in the case could effectively ban mifepristone nationwide and prevent healthcare providers from prescribing it even in states where abortion is legal.

Requires certified copies of the resolution to be transmitted to members of Hawaii's congressional delegation.